REG - Physiomics PLC - Notice of Results and Investor Presentation

PhysiomicsAnnouncement

22/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250922:nRSV1068Aa&default-theme=true

RNS Number : 1068A  Physiomics PLC  22 September 2025

22 September 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Notice of Results and Investor Presentation via Investor Meet Company

 

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science
company supporting the development of new therapeutics and personalised
medicine solutions, is pleased to announce that the Company will be releasing
its audited results for the year ended 30 June 2025, on 29 September 2025.

 

The Company further announces that following the merger of its previous
auditor, Shipleys LLP, with Moore Kingston Smith LLP ("MKS") and the
subsequent rebranding effective May 2025, MKS will serve as Physiomics'
auditors on an ongoing basis.

 

Dr Peter Sargent (CEO) and Dr Jim Millen (Non-Executive Chairman) will provide
a live presentation relating to the full year results and wider business
update via Investor Meet Company on 1 October 2025 at 12:00 BST.

The presentation is open to all existing and potential shareholders. Questions
can be submitted before the event via the Investor Meet Company dashboard up
until 30 September 2025, 09:00 BST, or at any time during the live
presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
PHYSIOMICS PLC via:

https://www.investormeetcompany.com/physiomics-plc/register-investor
(https://url6.mailanyone.net/scanner?m=1up0V0-00000004KCc-2xCa&d=4%7Cmail%2F90%2F1755763800%2F1up0V0-00000004KCc-2xCa%7Cin6c%7C57e1b682%7C24907477%7C9801997%7C68A6D64A93C723B1D1357285C2A869EC&o=%2Fphtw%3A%2Fwtstnw.resoivptmenomaechoy.s%2Fpycmpiiocs-lmceg%2Fr-streirotsevni&s=I6kwncWk6jomJvDpD5dpHIB3Cw8)

 

Investors who already follow PHYSIOMICS PLC on the Investor Meet Company
platform will automatically be invited.

 

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biometrics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOREAANNFAKSEFA



            Copyright 2019 Regulatory News Service, all rights reserved